ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

Date: Monday, November 14, 2016

Time: 2:30PM-4:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 2008
Rapamycin Elicits Rapid and Lasting Improvement of Disease Activity through Blocking Pro-Inflammatory T Cell Lineage Specification in Patients with Active SLE
Abstract Number: 2009
The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI–2K Responses and Continuous Measures of Activity As Outcome Measures
Abstract Number: 2010
Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Abstract Number: 2011
Enteric-Coated Mycophenolate Sodium Versus Azathioprine for Patients with Moderate/Severe Active Systemic Lupus Erythematosus: Results from a Phase 3, Randomized, Parallel, Multicentre Study
Abstract Number: 2012
Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
Abstract Number: 2013
BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE

« View all sessions from this meeting